Search research articles
Contact Us
Filters
Showing results (101-110 of 120) with videos related to
Page
of 12
Sort By:
Neuro-Oncology
|
January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Neurology
|
December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Andrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03
Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Matthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Eudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.
JAMA Oncology
|
October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Nature Medicine
|
July 10, 2026
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial
Michael Lim, Xiaobu Ye, Anna F Piotrowski, et al.
The Oncologist
|
October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Matthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Cancer Research Communications
|
July 10, 2023
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
Michal Nisnboym, Sarah R Vincze, Zujian Xiong, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 120) with videos related to
Sort By:
Page
of 12
Neuro-Oncology
|
January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Neurology
|
December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Andrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03
Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Matthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Eudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.
JAMA Oncology
|
October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Nature Medicine
|
July 10, 2026
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial
Michael Lim, Xiaobu Ye, Anna F Piotrowski, et al.
The Oncologist
|
October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Matthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Cancer Research Communications
|
July 10, 2023
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
Michal Nisnboym, Sarah R Vincze, Zujian Xiong, et al.
Page
of 12